Potential therapy of multidrug-resistant and extremely drug-resistant tuberculosis with thioridazine

In Vivo

Volumn 26, Issue 2, 2012, Pages 231-236

  Amaral, Leonard ^a   Molnar, Joseph ^b  

^a INSTITUTO DE HIGIENE E MEDICINA TROPICAL   (Portugal)

^b UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Drug resistant tuberculosis; MDRTB; Multidrug resistant tuberculosis; Phenothiazines; Thioridazine; XDRTB

Indexed keywords

CHLORPROMAZINE; ISONIAZID; LINEZOLID; METHYLENE BLUE; MOXIFLOXACIN; OUABAIN; PHENOTHIAZINE DERIVATIVE; RIFAMPICIN; THIORIDAZINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGRANULOCYTOSIS; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; BACTERIAL STRAIN; CARDIOTOXICITY; DEMENTIA; DISEASE COURSE; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MISUSE; DRUG WITHDRAWAL; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LUNG INFECTION; LUNG TUBERCULOSIS; MAXIMUM PLASMA CONCENTRATION; MENTAL DISEASE; MIXED INFECTION; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NEUROLEPTIC MALIGNANT SYNDROME; NONHUMAN; PHOTOTOXICITY; PROGNOSIS; PSYCHOSIS; QT INTERVAL; QUALITY OF LIFE; RETINOPATHY; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SOMNOLENCE; UNSPECIFIED SIDE EFFECT;

EID: 84857879092     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (73)

1. Drobniewski FA and Balabanova YM: The diagnosis and management of multiple drug-resistant tuberculosis at the beginning of the new millenium. Int J Infect Dis 6(Suppl 1): S21-31, 2002. (Pubitemid 40090868)
2. WHO/IUATLD Global Project on Anti-tuberculosis Drug Resistance Surveillance. Fourth Global report. Geneva, 2008.
3. Centers for Disease Control and Prevention [CDC]: Plan to combat extensively drug-resistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. Morb Mortal Wkly Rep 58(RR-3): 1-43, 2009.
4. Ehrlich P: The Collected Papers of Paul Erhlich. Himmelweit F, Marquait M and Dale H (eds.). London: Pergamon Press, pp. 500-508, 1956.
5. Guttmann P and Erhlich P: Über die Wirkung des Methylenblau bei Malaria. Berliner Klinische Wochenschrift 39: 953-956, 1891.
6. Amaral L, Viveiros M and Molnar J: Antimicrobial activity of phenothiazines. In Vivo 18: 725-732, 2004. (Pubitemid 40089621)
7. Kristiansen JE and Amaral L: The potential management of resistant infections with non-antibiotics. J Antimicrobial Chemother 40: 319-27, 1997. (Pubitemid 27437949)
8. Charpentier P, Gaillot P, Jacob R, Gaudechon J and Buisson P: Recherches sur les dimethylaminopropyl N-phenothiazines. Comptes Rendue Aux Academie Des Sciences 235: 59-60, 1952.
9. Amaral L, Viveiros M and Kristiansen J: Phenothiazines: potential alternatives for the management of antibiotic resistant infections of tuberculosis and malaria in developing countries. Trop Med Int Health 6: 1016-1022, 2001. (Pubitemid 34008769)
10. Amaral L, Kristiansen JE, Viveiros M and Atouguia J: Activity of phenothiazines against antibiotic resistant Mycobacterium tuberculosis: A review supporting further studies that may elucidate the potential use of thioridazine as an anti-TB agent. J Antimicrob Chemother 47: 505-507, 2001.
11. Kristiansen JE and Vergmann B: The antibacterial effect of selected phenothiazines and thioxanthenes on slow-growing mycobacteria. Acta Pathol Microbiol Immunol Scand [B] 94: 393-398, 1986. (Pubitemid 17008869)
12. Meindl W and Laske R: Antimycobacterial properties of phenothiazine type compounds Arch Pharm [Weinheim] 322: 133-136, 1989. (Pubitemid 19078041)
13. Chakrabarty AN, Bhattacharya CP and Dastidar SG: Antimycobacterial activity of methdilazine [Md], an antimicrobic phenothiazine. APMIS 101: 449-454, 1993. (Pubitemid 23255824)
14. Molnár J, Béládi I and Földes I: Studies on antituberculotic action of some phenothiazine derivatives in vitro. Zentralbl Bakteriol [Orig A] 239: 521-526, 1977.
15. Amaral L, Kristiansen JE, Abebe LS and Millett W: Inhibition of the respiration of multidrug-resistant clinical isolates of Mycobacterium tuberculosis by thioridazine: potential use for initial therapy of freshly diagnosed tuberculosis. J Antimicrob Chemother 38: 1049-1053, 1996. (Pubitemid 27073284)
16. Bettencourt MV, Bosne-David S and Amaral L: Comparative in vitro activity of phenothiazines against multidrug-resistant Mycobacterium tuberculosis. Int J Antimicrob Agents 16: 69-71, 2000. (Pubitemid 30665428)
17. Viveiros M and Amaral L: Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines. Int J Antimicrob Agents 17: 225-258, 2001.
18. Crowle AJ, Douvas GS and May MH: Chlorpromazine: a drug potentially useful for treating mycobacterial infections. Chemotherapy 35: 410-409, 1992.
19. Ordway D, Viveiros M, Leandro C, Arroz MJ and Amaral L: Chlorpromazine has intracellular killing activity against phagocytosed Staphylococcus aureus at clinical concentrations. J Infect Chemother 8: 227-231, 2002.
20. Ordway D, Viveiros M, Leandro C, Arroz MJ and Amaral L: Intracellular activity of clinical concentrations of phenothiazines including thioridiazine against phagocytosed Staphylococcus aureus. Int J Antimicrob Agents 20: 34-43, 2002. (Pubitemid 34778465)
21. Martins M, Bleiss W, Marko A et al: Ordway D, Viveiros M, Leandro C, Pacheco T, Molnar J, Kristiansen JE and Amaral L: Clinical concentrations of thioridazine enhance the killing of intracellular methicillin-resistant Staphylococcus aureus: an in vivo, ex vivo and electron microscopy study. In Vivo 18: 787-794, 2004. (Pubitemid 40089628)
22. Ordway D, Viveiros M, Leandro C and Amaral L: Clinical concentrations of thioridazine kill intracellular multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother 47: 917-922, 2003. (Pubitemid 36254216)
23. Martins M, Viveiros M, Ramos J, Couto I, Molnar J, Boeree M, Amaral L: SILA 421, an inhibitor of efflux pumps of cancer cells, enhances the killing of intracellular extensively drug-resistant tuberculosis [XDR-TB]. Int J Antimicrob Agents 33: 479-482, 2009.
24. Martins M, Viveiros M, Kristiansen JE, Molnar J and Amaral L: The curative activity of thioridazine on mice infected with Mycobacterium tuberculosis. In Vivo 21: 771-775. 2007.
25. van Sooligen D, Pando RH, Orozco H, Aguilar D, Magis C, van Ingen J, Amaral L and Boeree M: Thioridazine shows promising activity in a murine model of multi-drug resistant tuberculosis. Non-published observations.
26. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT and Rubin H: Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. Proc Natl Acad Sci USA 102: 4548-4553, 2005. (Pubitemid 40397149)
27. Thanacoody HK: Thioridazine: resurrection as an antimicrobial agent? Br J Clin Pharmacol 64: 566-574, 2007.
28. Motohashi N: Phenothiazines and calmodulin [review]. Anticancer Res 11: 1125-1164, 1991.
29. Hidaka H and Naito Y: Inhibitor of calmodulin and calmodulin dependent enzyme. Tanpakushitsu Kakusan Koso. 43(12 Suppl): 1732-1738, 1998.
30. MacNeil S, Lakey T and Tomlinson S: Calmodulin regulation of adenylate cyclase activity. Cell Calcium 6: 213-216, 1985.
31. Tate CA, Hyek MF and Taffet GE: The role of calcium in the energetics of contracting skeletal muscle. Sports Med 12: 208-217, 1991.
32. Matschinsky FM: Banting Lecture 1995. A lesson in metabolic regulation inspired by the glucokinase glucose sensor paradigm. Diabetes 45: 223-241, 1996.
33. Reddy PT, Prasad CR, Reddy PH, Reeder D, McKenney K, Jaffe H, Dimitrova MN, Ginsburg A, Peterkofsky A and Murthy PS: Cloning and expression of the gene for a novel protein from Mycobacterium smegmatis with functional similarity to eukaryotic calmodulin. J Bacterioi 185: 5263-5268, 2003. (Pubitemid 37021987)
34. Sarma PV, Sarma PU and Murthy PS: Isolation, purification and characterization of intracellular calmodulin like protein [CALP] from Mycobacterium phlei. FEMS Microbiol Lett 159: 27-34, 1998. (Pubitemid 28051341)
35. Teh JS, Yano T and Rubin H: Type II NADH: menaquinone oxidoreductase of Mycobacterium tuberculosis. Infect Disord Drug Targets 7: 169-181, 2007. (Pubitemid 47099126)
36. Zhu L, Zhang Y, Teh JS, Zhang J, Connell N, Rubin H and Inouye M: Characterization of mRNA interferases from Mycobacterium tuberculosis. J Biol Chem 281: 18638-18643, 2006. (Pubitemid 44035523)
37. Yano T, Li LS, Weinstein E, Teh JS and Rubin H: Steady-state kinetics and inhibitory action of antitubercular phenothiazines on mycobacterium tuberculosis type-II NADH-menaquinone oxidoreductase [NDH-2]. J Biol Chem 281: 11456-63, 2006. (Pubitemid 43855400)
38. Avarbock A, Avarbock D, Teh JS, Buckstein M, Wang ZM, Rubin H: Functional regulation of the opposing [p]ppGpp synthetase/hydrolase activities of RelMtb from Mycobacterium tuberculosis. Biochemistry 44: 9913-9923, 2005. (Pubitemid 41033458)
39. Wojcikowski J and Daniel WA: Thioridazine-fluoxetine interaction at the level of the distribution process in vivo. Pol J Pharmacol 54: 647-654, 2002. (Pubitemid 36124515)
40. distribution of psychotropic drugs in the grey and white matter of the brain: the role of lysosomal trapping. Br J Pharmacol 134: 807-814, 2001.
41. Wójcikowski J and Daniel WA: Distribution interactions between perazine and antidepressant drugs. In vivo studies. Pol J Pharmacol 52: 449-457, 2000. (Pubitemid 32045908)
42. Daniel WA and Wójcikowski J: Lysosomal trapping as an important mechanism involved in the cellular distribution of perazine and in pharmacokinetic interaction with antide-pressants. Eur Neuropsychopharmacol 9: 483-491, 1999. (Pubitemid 30089061)
43. Aszalos A: Drug-drug interactions affected by the transporter protein, P-glycoprotein [ABCB1, MDR1] II. Clinical aspects. Drug Discov Today 12: 838-843, 2007.
44. Aszalos A: Drug-drug interactions affected by the transporter protein, P-glycoprotein [ABCB1, MDR1] I. Preclinical aspects. Drug Discov Today 12: 833-837, 2007.
45. Liang XJ and Aszalos A: Multidrug transporters as drug targets. Curr Drug Targets 7: 911-921, 2006.
46. + channel and IKr of guinea pig cardiomyocytes by antipsychotic drug trifluoperazine. J Pharmacol Exp Ther 313: 888-895, 2005.
47. Landwojtowicz E, Nervi P and Seelig A: Real-time monitoring of P-glycoprotein activation in living cells. Biochemistry 41: 8050-8057, 2002. (Pubitemid 34655172)
48. +: modulation by sulfated polysaccharides and trifluoperazine. J Neurochem 66: 772-778, 1996.
49. Adhikary G, Nandy P, Chandra S, Sikdar R and Sen PC: The in vivo inhibition of transport enzyme activities in different organs of rat by chlorpromazine is reversible. Biochem Int 25: 951-961, 1991.
50. Mazumder B, Mukherjee S and Sen PC: The chlorpromazine inhibition of transport ATPase and acetylcholinesterase activities in the microsomal membranes of rat in vitro and in vivo. Mol Cell Biochem 95: 13-20, 1990. (Pubitemid 20171468)
51. +-ATPase pumping and solute transport in rat hepatocytes. Am J Physiol 253(5 Pt 1): G613-621, 1987.
52. Amaral L, Engi H, Viveiros M and Molnar J: Review. Comparison of multidrug resistant efflux pumps of cancer and bacterial cells with respect to the same inhibitory agents. In Vivo 27: 237-244, 2007. (Pubitemid 46534275)
53. Segal AW: How neutrophils kill microbes. Annu Rev Immunol 23: 197-223, 2005.
54. + channel is essential for innate immunity. Nature 427: 853-858, 2004.
55. Reeves EP, Lu H, Jacobs HL, Messina CG, Bolsover S, Gabella G, Potma EO, Warley A, Roes J and Segal AW: Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature 416: 291-297, 2002. (Pubitemid 34260237)
56. Aperia A: New roles for an old enzyme: Na, K-ATPase emerges as an interesting drug target. J Intern Med 261: 44-52, 2007.
57. Amaral L, Martins M and Viveiros M: Enhanced killing of intracellular multidrug-resistant Mycobacterium tuberculosis by compounds that affect the activity of efflux pumps. J Antimicrob Chemother 59: 123712-123746, 2007.
58. + transport enhance intracellular killing of M. tuberculosis by non-killing macrophages. In Vivo 22: 69-75, 2008
59. Martins M, Viveiros M, Couto I and Amaral L: Targeting the human macrophages for enhanced killing of intracellular XDT-TB and MDR-TB. Int J Tuberc Lung Dis 13: 1-5, 2009.
60. Kirchner V, Kelly CA and Harvey RJ: Thioridazine for dementia. Cochrane Database Syst Rev 3: CD000464, 2001.
61. Mackin P: Cardiac side-effects of psychiatric drugs. Hum Psychopharmacol 23(Suppl 1): 3-14, 2008.
62. Zemrak WR and Kenna GA: Association of antipsychotic and antidepressant drugs with Q-T interval prolongation. Am J Health Syst Pharm 65: 1029-1038, 2008. (Pubitemid 351768736)
63. Delieu JM, Horobin RW and Duguid JK: Formation of immature neutrophil leucocytes in schizophrenic patients treated with various antipsychotic drugs: comparisons and predictions. J Psychopharmacol 20: 824-828, 2006. (Pubitemid 44622747)
64. Gongadze N, Kezeli T and Antelava N: Prolong QT interval and "torsades de pointes" associated with different group of drugs. Georgian Med News 153: 45-49, 2007.
65. Migliori GB, Lange C, Centis R, Sotgiu G, Mütterlein R, Hoffmann H, Kliiman K, Delaco G, Lauria FN, Richardson MD, Spanevello A, Cirillo DM and TBNET Study Group: Resistance to second-line injectables and treatment outcomes in multidrug-resistant and extensively drug-resistant tuberculosis cases. Eur Respir J 31: 1155-1159, 2008.
66. Migliori GB, Lange C, Girardi E et al: Centis R, Besozzi G, Kliiman K, Ortmann J, Matteelli A, Spanevello A, Cirillo DM; SMIRA/TBNET Study Group: Extensively drug-resistant tuberculosis is worse than multidrug-resistant tuberculosis: different methodology and settings, same results. Clin Infect Dis 46: 958-959, 2008. (Pubitemid 351417212)
67. Kim HR, Hwang SS, Kim HJ et al: Lee SM, Yoo CG, Kim YW, Han SK, Shim YS and Yim JJ: Impact of extensive drug resistance on treatment outcomes in non-HIV-infected patients with multidrug-resistant tuberculosis. Clin Infect Dis 45: 1290-1295, 2007.
68. TBTC Study 24: Intermittent Treatment of TB With Isoniazid Resistance or Intolerance. Center for Disease Control and Prevention; Clinical Trials. Gov Identifier:NCT00023374, 2007.
69. Abbate E, Vescoso M, Natiello M, Cufre M, Garcia A, Ambroggi M, Poggi S, Simboli N and Ritacco V: Tuberculosis extensamente resistente (XDR-TB) en Argentina: aspectos destacbles epidemiologicos, bacteriologicos, terapeuticos y evolutivos. Revista Argentina de Medicina Respiratoria 1: 19-25, 2007.
70. van Soolingen D, Hernandez-Pando R, Orozco H, Aguilar D, Magis-Escurra C, Amaral L, van Ingen J and Boeree MJ: The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis. PLoS One. 5(9): pii:e12640, 2010.
71. Amaral L, Boeree MJ, Gillespie SH, Udwadia ZF and van Soolingen D: Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now! Int J Antimicrob Agents 35: 524-526, 2010.
72. Abbate E, Vescovo M, Natiello M, Cufré M, Garcia A, Gonzalez Montaner P, Ambroggi M, Ritacco V and van Soolingen D: Succesful alternative treatment of extensively drug-resistant tuberculosis in Argentina by a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother December 1, (Epub ahead of print) 2011.
73. Udwadia ZF, Sen T and Pinto LM: Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov 6: 88-91, 2011.